paclitaxel

Original Contribution

Outcomes Following Coronary Chronic Total Occlusion Revascularization With Drug-Coated Balloons

02/21/2024

Mehdi Madanchi, MD^1,2; Matthias Bossard, MD^1,2; Irena Majcen, PhD^1,2; Giacomo M. Cioffi, MD^1,3; Francesco Ferraro, MD⁴; Eleonora Gnan, MD^1,5; Varis Gjergjizi, MD¹; Yuan Zhi, MD¹; Vanessa Bade, BSc^1,6; Mathias Wolfrum, MD¹; Federico Moccetti, MD¹; Stefan Toggweiler, MD¹; Adrian Attinger-Toller, MD¹; Florim Cuculi, MD^1,2

Mehdi Madanchi, MD1,2; Matthias Bossa...

The study aimed to describe the safety and long-term outcomes of patients with coronary chronic total occlusions undergoing percutaneous coronary interventions with the latest generation of drug-coated balloons vs novel drug-eluting stents.

The study aimed to describe the...

02/21/2024

Journal of Invasive Cardiology

AMP 2023

Current Clinical Data on RANGER DCB: RANGER II SFA, COMPARE, and Real-World Experience with ELEGANCE

11/13/2023

Pradeep Nair, MD

Cardiovascular Institute of the South, Houma, Louisiana

Pradeep Nair, MD Cardiovascular Inst...

In this video recorded at AMP 2023, Dr. Pradeep Nair discusses his presentation on the clinical data available on the Ranger drug-coated balloon.

In this video recorded at AMP...

11/13/2023

Vascular Disease Management

Original Research

Clinical Performance of a Paclitaxel Drug-Coated Balloon in Real-World Percutaneous Coronary Intervention Practice: The PEARL Registry

06/01/2022

Selina Vlieger, MSc¹; Jin M. Cheng, MD, PhD²; Rohit M. Oemrawsingh, MD, PhD¹; Auke P.J.D. Weevers, MD¹; Jawed Polad, MD³; Ben Gho, MD, PhD⁴; Martijn Meuwissen, MD, PhD²; Peter den Heijer, MD, PhD²; Eric Boersma, PhD⁵; Alexander J.J. IJsselmuiden, MD, PhD²

Selina Vlieger, MSc1; Jin M. Cheng, ...

Randomized controlled trials for in-stent restenosis (ISR) and de novo lesions in small-diameter vessels have shown promising results, but data on DCB use in real-world practice are still scarce. The aim of the PEARL (Paclitaxel-Eluting...

Randomized controlled trials for...

06/01/2022

Journal of Invasive Cardiology

Original Contribution

Rationale and Design of the IN.PACT BTK Randomized Pilot Study: A Paclitaxel Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for Infrapopliteal Chronic Total Occlusions

06/08/2021

Antonio Micari, MD, PhD¹; Jeffrey J. Popma, MD²; Francesco Liistro, MD³

Antonio Micari, MD, PhD1; Jeffrey J....

This is a pilot feasibility study and the objective is to evaluate the safety and effectiveness of the investigational device, IN.PACT 014 drug-coated balloon, compared with standard PTA in patients with CLI with CTOs of BTK arteries.

This is a pilot feasibility...

06/08/2021

Cath Lab Digest

Commentary

The Paclitaxel-Coated Conundrum: A Commentary Article

01/14/2020

Michael Patel, MD^1; Robert Beasley, MD, FSIR, FSCAI²

¹Department of Interventional Radiology, Mount Sinai Medical Center, Miami Beach, Florida; ²Robert Beasley, Section Chief, Vascular/ Interventional Radiology, Mount Sinai Medical Center, Miami Beach, Florida

Michael Patel, MD1; Robert Beasley, M...

Michael Patel, MD, and Robert Beasley, MD discuss drug-eluting stents and drug-coated balloons.

Michael Patel, MD, and Robert...

01/14/2020

Vascular Disease Management

FDA Panel

The Future is Going to Be Drug-Coated or Drug-Eluting. We Need Individual Patient Data to Move Forward.

06/27/2019

Konstantinos Katsanos, MSc, MD, PhD, EBIR

Assistant Professor, Interventional Radiology, School of Medicine, Patras University Hospital, Patras, Greece

Konstantinos Katsanos, MSc, MD, PhD, ...

VDM talks with Konstantinos Katsanos, MSc, MD, PhD, EBIR, Assistant Professor, Interventional Radiology, School of Medicine, Patras University Hospital, Patras, Greece.

VDM talks with Konstantinos...

06/27/2019

Vascular Disease Management

FDA Panel

My View: Paclitaxel Use in Peripheral Arterial Disease

06/24/2019

Richard R. Heuser, MD, FACC, FACP, FESC, MSCAI

Chief of Cardiology, St. Luke's Medical Center; Professor of Medicine, University of Arizona School of Medicine; Phoenix Heart Center, Phoenix, Arizona

Richard R. Heuser, MD, FACC, FACP, FE...

Dr. Richard Heuser comments on the use of paclitaxel in peripheral arterial disease.

Dr. Richard Heuser comments on...

06/24/2019

Vascular Disease Management

Research in Review

Switching From Docetaxel to Paclitaxel and Bevacizumab Improves PFS in NSCLC

12/08/2016

JCP Editors

Patients with non-squamous non-small cell lung cancer (NSCLC) have improved progression-free survival (PFS) if they switch from docetaxel to paclitaxel and bevacizumab treatments, according to new...

...

12/08/2016

Journal of Clinical Pathways